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Abstract
The reaction of mercaptoacetic acid esters with pentachloro-2-nitro-1,3-butadiene (1) provides an appropriate precursor for the syn-
thesis of special thiazolidin-4-ones. Applying different anilines as the second constituent for the requisite cyclization step, a series
of (Z)-2-allylidenethiazolidin-4-ones was obtained in yields up to 81%. Some subsequent reactions have been examined too, such as
the formation of perfunctionalized 1H-pyrazoles upon treatment with hydrazine. Thiazolidinones are as well known for their physi-
ological activities as for their application in optoelectronics.
Introduction
Preliminary studies in the field of polyhalogenated nitrobutadi-
enes have already shown the enormous potential of pentachloro-
2-nitro-1,3-butadiene (1) as a precursor for the “click synthesis”
of highly functionalized (hetero)cyclic as well as acyclic com-
pounds [1-15]. The corresponding syntheses that we have
developed up to now [2-13], always start with the attack of an
appropriate nucleophile at the activated terminal carbon atom of
the nitrodichlorovinyl group within 1 to undergo a vinylic
substitution. Thus, in case of, e.g., sulfur nucleophiles, the
corresponding thioperchlorobutadiene derivatives are easily
accessible [2,5,16,17]. In this paper, we describe the formation
of uniquely substituted thiazolidin-4-ones, a class of com-
pounds which has proven to exhibit distinctive bioactivity, e.g.,
antifungal, antibacterial, antitubercular, and anticonvulsant
properties [18-28].
Additionally, more recent studies often focus on their anti-
cancer [29-31] and anti-HIV potential [30,32]. Several 4-thiazo-
lidinone derivatives such as ralitoline (anticonvulsant), etozo-
line (antihypertensive), pioglitazone (hypoglycemic) and thia-
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Scheme 1: SNVin reactions of pentachloro-2-nitro-1,3-butadiene (1).
zolidomycin (activity against streptomyces species) are already
in the market [33]. Beyond that, among industrial applications
thiazolidinones serve as electron donors, e.g., as ligands in
coordination compounds or as vulcanizing agents [31]. Further-
more, it is well known that these heterocycles play a major role
in corresponding organic electronics, e.g., they lead to high
quantum efficiency as donor compound in solar cells [34]. Very
recently, thiazolidinones became a target in the field of
photonics and optoelectronics, potentially applicable for revers-
ible optical data storage, photo switching of optical elements,
photochromic polymers, and similar applications [35].
The background of thiazolidinone chemistry including classical
synthetic strategies has been reviewed comprehensively [18-
28,36-39]. Even though among possible synthetic pathways the
use of mercaptoacetic acid and its derivatives is well-estab-
lished [40-44], our approach, starting from a mercaptoacetic
acid derivative of perchloro-2-nitro-1,3-butadiene and an
aniline, is unprecedented up to now. In this context, it is very
interesting that the reaction of a 2-nitro-1-thioperchlorobuta-
1,3-diene with N-nucleophiles usually yields a 1-amino-2-nitro-
1-thioperchlorobuta-1,3-diene [16,45]. However, our novel ring
closing reaction incorporates an arylamine as source for the
nitrogen of the thiazolidin-4-one heterocycle.
Results and Discussion
The reaction of pentachloro-2-nitro-1,3-butadiene (1) with
1.1 equivalents of ethyl 2-mercaptoacetate (2) at room tempera-
ture without a solvent for 10 days furnished ethyl 2-((1,3,4,4-
tetrachloro-2-nitrobuta-1,3-dien-1-yl)thio)acetate (3) as a single
isomer in 80% yield (for further details see Supporting Informa-
tion File 1). In contrast, the conversion of 1 (neat) with
2.1 equivalents of methyl 2-mercaptoacetate (4) results in a
mixture of methyl 2-((1,3,4,4-tetrachloro-2-nitrobuta-1,3-dien-
1-yl)thio)acetate (5) and 1,1-bis(methoxycarbonylmethylthio)-
2-nitro-3,4,4-trichlorobuta-1,3-diene (6) after 10 days at room
temperature with 67% and 29% yields, respectively. These
nitrodienes 5 and 6 were separated by flash column chromatog-
raphy and then characterized. Interestingly, the dithio com-
pound 6 was also accessible by treatment of the aforemen-
tioned monothio derivative 5 with one equivalent of mercap-
toacetate 4. Following this pathway, the disubstituted diene 6
was obtained in 80% yield (Scheme 1).
The subsequent reaction of the mercaptoacetates 3 and 5 with
2.1 equivalents of various arylamines is the key step of our thia-
zolidin-4-one synthesis, that led to the corresponding (Z)-3-aryl-
2-(2,3,3-trichloro-1-nitroallylidene)thiazolidin-4-ones 7–18
with up to 81% yield. As an example for the sequential reactiv-
ity of the persubstituted allylidene side chain, the thiazolidin-4-
one 15 was reacted with p-tolylthiolate. Thereby, the C(2)–Cl
position of the allylidene group was selectively substituted
by the reactive thiolate nucleophile, again in a SNVin-type
process, to give (Z)-3-(4-tolyl)-2-(3,3-dichloro-1-nitro-2-[4-
tolylthio]allylidene)thiazolidin-4-one (19) in 70% yield
(Scheme 2).
According to proton NMR, the ring-closing step with the parent
aniline or with one of its para-substituted derivatives in each
case led to a single N-arylthiazolidin-4-one isomer 7–15. In the
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Scheme 2: Formation of thiazolidin-4-ones 7–19.
case of the ortho- or meta-substituted anilines 16–18 two atrop-
isomers were generated. This phenomenon is due to a less
hindered rotation of the C–N bond of the former anilines
(Figure 1).
Figure 1: Hindered rotation in the case of ortho- or meta-substituted
aniline precursors.
The steric hindrance is additionally forcing by the s-cis con-
formation of the nitrobutadiene moiety (cf. Figure 2). A DFT
calculation of the energy barrier for rotation of the aromatic
substituent resulted in extraordinary high values of 169 and
191 kJ/mol for the ortho-methyl compound 18 and the larger,
but less rigid ortho-methoxy derivative 16, respectively. As
expected, the meta-anisyl derivative 17 showed a lower barrier
of 73 kJ/mol (see Supporting Information File 1). For compari-
son, the well-known atropisomer 1,1’-binaphthalene-2,2’-diol
(BINOL) shows a rotational barrier of 158 kJ/mol with calcu-
lated data in good accordance with the experimental value [46].
In addition to substantial NMR, IR, and mass spectral character-
ization of the thiazolidinones 7–18, as an example the
4-iodophenyl substituted thiazolidinone 11 was subjected to
X-ray analysis (see Supporting Information File 1). This
confirmed the Z-configuration of the inner double bond which
bears the sulfur atom of the hetero ring as well as the nitro
group. The structural plot also gives an idea of the abovemen-
tioned bulkiness, even in the case of the depicted para-substitu-
tion (Figure 2).
Figure 2: X-ray analysis of thiazolidin-4-one 11.
The formation of the thiazolidin-4-ones 7–18 is assumed to
consist of three individual steps. In a SNVin type reaction with
the aniline derivative intermediate A (Scheme 3) is formed.
Subsequently, the thus introduced amino group attacks the car-
bonyl carbon of the mercaptoacetate moiety. This ring closure
affords the temporary imide hemiacetal B which is then stabi-
lized upon elimination of the corresponding alcohol to give the
desired thiazolidin-4-ones 7–18 (Scheme 3).
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Scheme 3: Assumed mechanism for the formation of thiazolidin-4-ones 7–18.
Scheme 4: Substitution reactions of the precursors 3 and 5 with additional amines.
Furthermore, in addition to the anilines described above
(Scheme 2), we applied 1-naphthylamine as a bulkier aromatic
representative and morpholine as a secondary, more basic ali-
phatic amine. Conversion of 3 and 5 with morpholine and
1-naphthylamine afforded the open chain products 20 and 21 in
93% and 80% yield, respectively (Scheme 4), without a subse-
quent cyclization under one-pot conditions. Unexpectedly, even
under forcing conditions cyclization of isolated 21 did not take
place. Compound 21 was exclusively obtained as E-isomer.
This was indicated by a proton NMR signal shifted downfield to
about 12 ppm due to a strong hydrogen bond between the amino
hydrogen and the nitro group. In contrast, lacking the opportu-
nity to build such a hydrogen bridge, the regiochemistry of
compound 20 (also formed as one single isomer) remained
unclear.
With the thiazolidinones in hand, in the case of 7, 8, 10, and 12
we carried out a Knoevenagel-type condensation with benzalde-
hyde and 3,4-dichlorobenzaldehyde in acetic acid at 118 °C in
the presence of triethylamine. Thus, the 5-arylmethylidenethia-
zolidin-4-ones 22–26 were obtained in 68–94% yield. The pres-
ence of only one signal for the benzylidene proton at
7.83–7.98 ppm in the 1H NMR spectra of 22–26 suggested the
formation of a single isomer, which was assigned to the Z-con-
figuration according to the literature for similar compounds
[47,48]. Interestingly, close analogues of these structures, i.e.,
the 5-arylmethylidene rhodanines, possess photosynthesis-
inhibiting and antialgal properties [49], show anticancer activity
[50,51], and are inhibitors of bacterial enzyme synthetase MurD
with E. coli [52].
Additional treatment of thiazolidin-4-one 8 with a fivefold
excess of hydrazine hydrate resulted in the formation of a
1H-pyrazole: A total of two hydrazine molecules were incorpo-
rated into the final product, whereas two additional equivalents
were consumed capturing hydrochloric acid. In this way, the
1H-pyrazole 27 with an exceptional substitution pattern was
obtained in 64% yield. The same reaction was applied to 5-aryl-
methylidene-thiazolidin-4-one 25 which furnished the corres-
ponding 1H-pyrazole 28 in 52% yield (Scheme 5).
A plausible multistep mechanism of this conversion is shown in
Scheme 6: Initially, a first molecule of the strong nucleophile
hydrazine is assumed to substitute the single C–Cl group within
the trichlorovinyl subunit of 8 to give the intermediate I (SNVin
reaction). Thereby, a second equivalent of hydrazine captures
hydrochloric acid. The amino group of the hydrazone then
attacks the electrophilic C-2 position of the thiazolidinone. This
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Scheme 5: Synthesis of 5-arylmethylidenethiazolidin-4-ones 22–26 and 1H-pyrazoles 27, 28.
Scheme 6: Assumed mechanism for the formation of 1H-pyrazole 27.
way a threefold substituted 1H-pyrazole is formed (intermedi-
ate II) under ring opening of the thiazolidinone. In the course of
the reaction, probably at this stage, the N-aryl amide is hydrazi-
nolysed to give the intermediate III, which is converted into the
monohydrazino compound IV upon consumption of two further
equivalents of hydrazine. Finally, 27 is obtained upon elimina-
tion of hydrochloric acid, caught by a fifth equivalent of
hydrazine (Scheme 6). An analogous mechanism is also plau-
sible for the formation of pyrazole 28 from thiazolidinone 25.
However, instead of the elimination of 2-mercaptoacetic acid
from intermediate II, in the latter case 3-(3,4-dichlorophenyl)-
2-mercaptoacrylic acid is released.
Moreover, nitrodiene 1 was subjected to a vinylic substitution
with ethyl 2-mercaptopropanoate to give ethyl 2-[(1,3,4,4-tetra-
chloro-2-nitrobuta-1,3-dien-1-yl)thio]propanoate (29) as an
inseparable mixture of Z- and E-isomers in a 4:1 ratio with 78%
total yield. Treatment of dienes (Z,E)-29 with different anilines
in ethanol at 0 °C to rt furnished (Z,E)-3-aryl-5-methylthiazo-
lidinones 30–32. As an example, thiazolidinone 32 was reacted
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Scheme 7: Formation of ethyl propanoate 29 and subsequent reactions.
with 4-chlorothiophenol in the presence of sodium ethoxide to
give 4-chlorophenylthio compound 33 (60%), again as a mix-
ture of Z- and E-isomers, but this time in a 2:1 ratio (Scheme 7).
Conclusion
A two-step synthesis of 2-allylidene-N-arylthiazolidinones 7–18
has been developed, starting from our building block 2-nitroper-
chlorobutadiene (1), 2-mercaptoacetates 2 and 4, and anilines.
Inclusion of o- or m-substituted N-aryl groups leads to the for-
mation of stable thiazolidinone atropisomers, due to hindered
rotation between the trichlorovinyl and the arylamino groups.
X-ray analysis proved the Z-configuration of the nitrovinyli-
dene group of 11. Subsequent reactions of the thiazolidinones,
such as the SNVin thiolation in 2-position of the allylidene
backbone, Knoevenagel condensation of the heterocyclic rings
with aromatic aldehydes, and an unusual formation of persubsti-
tuted pyrazoles demonstrate the chemical versatility of these
heterocyclic systems. The newly formed thiazolidinones
deserve additional synthetic interest as starting materials, also
due to their trichlorovinyl group. Tests on their physiological
activities and potential applications as optoelectronic materials
are on the way.
Supporting Information
Supporting Information File 1
Experimental part.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-10-170-S1.pdf]
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